Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • ECO
    --Site Admin--
    • Oct 2007
    • 1360

    #1

    Helicos ready to launch Heliscope! Stock market reacts 24 hours early!

    According to their presentation at the JP Morgan Healthcare Conference today, Helicos is ready to launch nearly nine instruments, for which they have no orders for. Please read the full report over at Genome Web: http://www.genomeweb.com/issues/news/144376-1.html

    I have a couple things to say here...the first of which is I am intrigued by the 40% jump in HLCS stock starting yesterday afternoon, on absolutely no news, other than the the DOW in general rallied in the afternoon. Looks like the news of this "launch is still a go" announcement leaked out something fierce.



    Also, I'm still waiting for a publication or any in depth treatment on how the Heliscope chemistry works. Compared to the pre-launch environment of the SOLiD system, Helicos has publicized virtually nothing about the chemistry, even in broad strokes.

    It's a bit disturbing that they are ready to launch the instrument but haven't published any data nor identified any pre-launch instrument placements.

    Their recent announcement of a $20M loan from GE leaves me wondering if they are close to death....if their cash burn rate was ~$10 million in Q3-2007, I would expect it to be significantly higher than that for Q4-2007 and Q1-2008. Meaning that $20M ain't going to last that long.

    But if I'm mistaken on any of these points, I would be glad to hear it (*hint*...register and post! )
  • ECO
    --Site Admin--
    • Oct 2007
    • 1360

    #2
    To respond to myself, I was mistaken. Apparently the market reaction on Jan 9 was based on data that Helicos published in their 8K released on Jan 9:

    Comment

    Latest Articles

    Collapse

    • SEQadmin2
      Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
      by SEQadmin2



      Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

      Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
      ...
      10-14-2026, 09:55 AM
    • SEQadmin2
      New Genomics Technologies Take Aim at Long-Standing Limits
      by SEQadmin2


      Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

      We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
      ...
      09-28-2026, 10:25 AM

    ad_right_rmr

    Collapse

    News

    Collapse

    Topics Statistics Last Post
    Started by SEQadmin2, 10-15-2026, 10:52 AM
    0 responses
    26 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 10-14-2026, 05:39 AM
    0 responses
    32 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 10-13-2026, 09:56 AM
    0 responses
    31 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 10-09-2026, 11:14 AM
    0 responses
    28 views
    0 reactions
    Last Post SEQadmin2  
    Working...